Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese bulk aspirin

This article was originally published in The Tan Sheet

Executive Summary

Jilin Henghe Pharmaceutical and Shandong Xinhua Pharmaceutical did not sell bulk aspirin in the U.S. "below normal value" from July 1, 2001 through June 30, 2002, International Trade Administration says Aug. 13. ITA determines no antidumping duties should be imposed on the two Chinese companies; antidumping margin of 144% applicable to other bulk aspirin exporters based in the People's Republic of China remains unchanged. In July 2000, U.S. Customs service imposed antidumping duties of 16.5% on Shandong, 10.9% on Jilin (1"The Tan Sheet" July 3, 2000, p. 2)...

You may also be interested in...



Aspirin dumping

U.S. Customs service will impose antidumping duties on bulk aspirin imports from China following a June 22 ITC determination the imports threaten U.S. industry with material injury. In an amended final determination June 21, the ITA revises previously announced weighted-average dumping margins for two Chinese firms: Shandong Xinhua Pharmaceutical Factory, 16.5% (previously 42.8%) and Jilin Pharmaceutical, 10.9% (previously 4.7%). The PRC-wide rate of 144% is unchanged (1"The Tan Sheet" May 29, In Brief)

Crunch Time For Protection Of New Therapeutic Uses In Europe

The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.

Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

Topics

UsernamePublicRestriction

Register

PS095811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel